September 11, 2019 — ViewRay Inc. announced that the company's MRIdian and MRIdian Linac magnetic resonance imaging (MRI)-guided radiation therapy systems will be featured at the 2019 annual meeting of the American Society for Radiation Oncology (ASTRO), Sept. 15-19 in Chicago. The meeting will feature a number of presentations highlighting the capabilities, clinical experience and patient outcomes with ViewRay's MRIdian and MRIdian Linac.
First introduced by ViewRay in 2012, MRI-Guided ROAR (Real-time On-table Adaptive Radiotherapy) represents a new paradigm in cancer treatment, according to the company. It provides clinicians with the ability to improve targeting precision and accuracy to deliver higher, and potentially more effective, radiation doses.
At this year's ASTRO, more than 20 scientific session presentations/posters will highlight the role of MRIdian in cancer treatment, including the value of its MRI-guidance, targeted dose delivery and automated beam gating. With the added clarity provided by MRIdian real-time imaging, physicians are better equipped to account for any motion caused by respiration or other bodily processes and personalize each treatment.
An ASTRO Industry Expert Theater session will feature two talks on the role of MRIdian in the treatment of prostate and pancreatic cancer. The first by Ben Slotman, M.D., Ph.D., from Amsterdam University Medical Centers is titled "MR-Guided Daily Adaptive SBRT for Prostate Cancer - A Phase 2 Prospective Study," and the second by Michael Chuong, M.D., from Miami Cancer Institute, Baptist Health South Florida is titled "MR-Guided SBRT for Pancreas with On-table Adaptation on MRIdian - MCI Experience."
ViewRay's booth will feature presentations from eight MRIdian users covering a wide range of topics and indications.
For more information: www.viewray.com
July 24, 2024 
